Low-dose tissue plasminogen activator and standard-dose tissue plasminogen activator in acute ischemic stroke in asian populations: A review

Cerebrovascular Diseases

Volumn 36, Issue 3, 2013, Pages 161-166

  Ramaiah, Siva Seeta ^a   Yan, Bernard ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Acute ischemic stroke; Asian population; Low dose tissue plasminogen activator; Standard dose tissue plasminogen activator; Thrombolysis

Indexed keywords

ALTEPLASE; DUTEPLASE; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; ASIA; ASIAN; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; JAPAN; JAPANESE; LOW DRUG DOSE; MAGNETIC RESONANCE ANGIOGRAPHY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PILOT STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; RANKIN SCALE; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; COHORT ANALYSIS; CONSENSUS; EUROPE; INCIDENCE; META ANALYSIS; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROIMAGING; NONHUMAN; NORTH AMERICA; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE PATIENT; SYMPTOM; UNCERTAINTY;

ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84886435913     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000354162     Document Type: Review

References (35)

1. Donnan G, Fisher M, Macleod M, Davis S: Stroke. Lancet 2008; 371: 1612-1623.
2. Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-1276.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
4. Saver JL: Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004; 61: 1066-1070.
5. Hacke W, Kaste M, Bluhmki E, et al: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
6. Poungvarin N: Stroke in the developing world. Lancet 1998; 352(suppl III):19-22.
7. Feigin VL: Stroke epidemiology in the developing world. Lancet 2005; 365: 2160-2161.
8. Ueshima S, Matsuo O: The differences in thrombolytic effects of administrated rt-PA between Japanese and Caucasians. Thromb Haemost 2002; 87: 544-546.
9. Clark WM, Wissman S, Albers GW, et al: Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 1999; 282: 2019-2026.
10. Yamaguchi T, et al: Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37: 1810-1815.
11. Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Sasaki M, Hirano T, et al: Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion. Japan Alteplase Clinical Trial II (J-ACT II). Stroke 2010; 41: 461-465.
12. Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al: Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice. The Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41: 1984-1989.
13. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R, Marler JR: Urgent therapy for stroke. 1. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632-640.
14. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, Torner JC, Marler JR: Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23:641-645.
15. Khatri P, Broderick JP, Pancioli AM: Risk of thrombolysis-associated intracerebral hemorrhage: the need to compare apples with apples. Stroke 2005; 36: 1109-1110.
16. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A: Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976-976.
17. Yamaguchi T, Hayakawa T, Kiuchi H: Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 1993; 3: 269-272.
18. Yamaguchi T, Hayakawa T, Kiuchi H: Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomized, double-blind, dose comparison study of duteplase; in Yamaguchi T, et al (eds): Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo, Springer, 1995, pp 223-229.
19. Wahlgren N, Ahmed N, Dvalos A, Ford GA, Grond M, Hacke W, Hennerici MG, et al: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
20. Chao AC, Hsu HY, Chung CP, Liu CH, Chen CH, Teng MM, et al: Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTTAIS) study. Stroke 2010; 41: 885-890.
21. Nguyen TH, Truong ATL, Ngo MB, et al: Patients with thrombolysed stroke in Vietnam have an excellent outcome: results from the Vietnam Thrombolysis Registry. Eur J Neurol 2010; 17: 1188-1192.
22. Chen C-H, Hsieh C-Y, Lai T-B, Chuang M-T, Chen W-L, Sun M-C: Optimal dose for stroke thrombolysis in Asians: low dose may have similar safety and efficacy as standard dose. J Thromb Haemost 2012; 10: 1270-1275.
23. Zhou XY, Wanga SS, Collins ML, Davis SM, Yan B: Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. J Clin Neurosci 2010; 17: 988-992.
24. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W, ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, et al: Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
25. Sharma VK, Tsivgoulis G, Tan JH, Ong BKC, Chan BPL, Teoh HL: Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore. J Stroke Cerebrovasc Dis 2010; 19: 424-430.
26. Pan S-M, Liu J-F, Liu M, Shen S, Li H-J, Dai L-H, Chen X-J: Efficacy and safety of a modified intravenous recombinant tissue plasminogen activator regimen in Chinese patients with acute ischemic stroke. J Stroke Cerebrovasc Dis 2013; 22: 690-693.
27. Suwanwela NC, Phanthumchinda K, Likitjaroen Y: Thrombolytic therapy in acute ischemic stroke in Asia: the first prospective evaluation. Clin Neurol Neurosurg 2006; 108: 549-552.
28. Murata M: Genetic polymorphisms associated with thrombotic disorders in the Japanese population. Fibrinol Proteol 2000; 14: 155-164.
29. Ikram MA, Seshadri S, Bis JC, Fornage M, DeStefano AL, Aulchenko YS, et al: Genomewide association studies of stroke. N Engl J Med 2009; 360: 1718-1728.
30. Matsushita T, Umeno J, Hirakawa Y, Yonemoto K, Ashikawa K, Amitani H, Ninomiya T, et al: Association study of the polymorphisms on chromosome 12p13 with atherothrombotic stroke in the Japanese population. J Hum Genet 2010; 55: 473-476.
31. Wong LKS: Global burden of intracranial atherosclerosis. Int J Stroke 2006; 1: 158-159.
32. Durai Pandian J, Padma V, Vijaya P, Sylaja PN, Jagaralpudi MKM: Stroke and thrombolysis in developing countries. Int J Stroke 2007; 2: 17-26.
33. Yoneda Y, Yamamoto S, Hara Y, Ohta K, Matsushita M, Yamamoto D, et al: Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit. Clin Neurol Neurosurg 2007; 109: 567-570.
34. Toyoda K, Koga M, Naganuma M, et al: Routine use of intravenous low dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI Register. Stroke 2009; 40: 3591-3595.
35. Iso H, Folsom AR, Koike KA, Sato S, Wu KK, Shimamoto T, Iida M, Komachi Y: Antigens of tissue plasminogen activator and plasminogen activator inhibitor 1: correlates in nonsmoking Japanese and Caucasian men and women. Thromb Haemost 1993;70:475.